原发性肝癌发病机制与管理的里程碑
本文综述原发性肝癌(肝细胞癌与肝内胆管癌)在发病机制、早期检测、诊断、分期和治疗方面的重大进展。肝细胞癌系统治疗药物不断涌现,肝内胆管癌的分子发病机制认识及辅助治疗和新系统治疗也取得突破。
要点
- 肝细胞癌与肝内胆管癌的分子驱动异常图谱已被揭示。
- 晚期肝细胞癌系统治疗药物包括索拉非尼、仑伐替尼等。
- 肝内胆管癌辅助治疗可用卡培他滨,系统治疗可用吉西他滨联合顺铂。
核心结论
- 原发性肝癌在发病机制、早期检测、诊断、分期和治疗方面取得了巨大进步。
- 晚期肝细胞癌管理因有效系统治疗的出现而显著改变。
- 肝内胆管癌的分子发病机制认识及治疗进展为患者管理创新铺平道路。
研究设计与样本
- 综述类文章,旨在突出原发性肝癌医学史上的主要里程碑并报告本期特刊的最新进展。
主要发现
- 肝细胞癌和肝内胆管癌的分子驱动异常图谱已被揭示。
- 肝细胞癌在预防、监测和治疗方面出现了若干突破。
- 过去十年晚期肝细胞癌管理因索拉非尼、仑伐替尼、瑞戈非尼、卡博替尼和雷莫芦单抗等有效系统治疗的出现而显著改变。
- 肝内胆管癌长期被认为是治疗选择有限的难治疾病,但分子发病机制认识、辅助治疗(卡培他滨)和新系统治疗(吉西他滨和顺铂)的发展为其管理创新铺平道路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver cancer is a major global health problem whose incidence is on the rise. The improvement in the understanding of the pathogenesis, early detection, diagnosis, staging and treatment of liver cancer has been enormous. The landscape of molecular aberrations driving both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) have been unravelled. Several breakthroughs have occurred in the prevention, surveillance and treatment of HCC. Particularly, management of patients at advanced stages has changed dramatically during the last decade with the advent of effective systemic therapies such as sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab. iCCA has long been considered a difficult to treat disease with few therapeutic options. However, recent advances in our understanding of its molecular pathogenesis, as well as the development of adjuvant therapy (capecitabine) and new systemic treatments (gemcitabine and cisplatin) have paved the way for further innovations in the management of patients with iCCA. In this manuscript, we aimed to highlight the main milestones in the medical history of primary liver cancer and report the most recent developments described within this special issue.
引用
- Nault JC, Cheng AL, Sangro B, et al. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol. 2020. PMID: 31954486. doi:10.1016/j.jhep.2019.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。